A new study that only included women with a cervix has found the risk of dying from cervical cancer is higher than previously thought.
Despite improved overall survival with standard of care, less than half of patients with locally advanced cervical cancer receive SOC treatment.
HPV DNA testing recommended in all resource settings; HIV should undergo screening more often
Human papillomavirus (HPV)-negative women have low long-term incidence of cervical cancer and CIN3+, which supports an extension of the cervical screening interval beyond five years for some, according to a study.
The vaccine against human papillomavirus (HPV) infection appears even more effective than previously believed and protection appears to occur even when only one or two of the recommended doses are given.
HIV is associated with reduced cancer-specific survival among women with invasive cervical cancer.
Despite confirmation of a link between routine Pap smear screening and a lower risk of developing cervical cancer in women older than 65 years, most US health guidelines discourage older women from undergoing routine Pap smears unless they have pre-existing risk factors.
Fewer cervical cell anomalies were present on cervical cancer screens of young women in Canada who received the HPV vaccine through a school-based program.
Cervical cancer, and oropharyngeal cancers in men, account for most HPV-associated cancers.
The addition of a patient navigation component to a population-based IT system boosted screening rates for breast cancer, cervical cancer, and colorectal cancer in patients at high risk for nonadherence.
ASCO has published its first clinical practice guideline on invasive cervical cancer, and the guidelines are the first to offer treatment recommendations tailored to resource availability.
A protein has been identified that can inhibit cellular inflammation, a major contributor to the growth of cervical cancer.
The American Society for Clinical Oncology has developed guidelines for the management and palliative care of women diagnosed with invasive cervical cancer.
Although HPV vaccination is expected to decrease the cancer burden from HPV across all racial and ethnic groups, some disparities are expected to persist and widen if their causes are not addressed, including lack of access to screening, timely diagnoses, and treatment.
A potential link between long-term oral treatment with nucleos(t)ide analogues for chronic hepatitis B virus (HBV) and an increased risk of colorectal and cervical cancers was demonstrated.
In patients with cervical cancer who do not have enlarged lymph nodes, SPECT-MRI imaging of their sentinel lymph nodes (SLNs) could assess whether metastases are present.
Offering free pap smears for cervical cancer screening did not increase pap smear frequency in low income women, even though low income and socioeconomic status are more likely to predict women skipping pap smears.
Follow-up of people whose screening examinations showed abnormal findings occurred faster for breast cancer than for colorectal and cervical cancers, according to a recent study involving more than 1 million people who underwent screening for these cancers.
Adherence to cancer screening recommendations was not found to vary by race/ethnicity and body weight/obesity. In a focused look at the influence of body mass index (BMI) as a measure of obesity, some screening disparities may be decreasing.
Incidence of Undetected Cancer in Patients Undergoing Gynecologic Surgery for a Benign Condition Higher Than EstimatedDecember 04, 2015
Researchers in Massachusetts sought to determine how frequently cancer is diagnosed in women after undergoing gynecologic surgery for a problem believed to be benign.
Affordable Care Act (ACA) Impacts Stage at Diagnosis and Fertility-Sparing Treatment in Young Women With Cervical CancerNovember 30, 2015
Both the stage of cervical cancer at diagnosis and the receipt of fertility-sparing treatment among young women age 21 to 25 years, but not among women age 26 to 34 years, is associated with the Affordable Care Act Dependent Coverage Expansion provision.
Scientists used a genetically engineered vaccine to successfully eradicate high-grade precancerous cervical lesions in nearly one-half of women who received the vaccine in a clinical trial.
A better understanding of the association between barriers to care and clinical outcomes within patient navigation programs.
A patient navigator program was successful in lowering the rate of missed appointments for cervical cancer evaluation following a Pap smear by twenty percent.
Women with cervical or endometrial cancer can safely receive extended-field intensity modulated radiation therapy (EF-IMRT) without increased risk of duodenal toxicity.
Fatalistic beliefs may affect completion of the human papillomavirus (HPV) vaccine series in some areas of the United States.
A decrease in cervical lesions among young women in the United States has been observed, but the cause for this drop is not proven.
Incidence of high-grade cervical lesions in young women has significantly decreased, but the declines were likely due to reduced screening.
One dose of the HPV vaccine may be sufficient to protect girls from cervical cancer rather than the currently recommended three doses.
Low-income and women without insurance in states that are not expanding their Affordable Care Act (ACA) Medicaid coverage are less likely to receive breast and cervical cancer screenings.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|